Additionally, SYD exerts control over the IL‐17/TNF/NF‐κB signaling pathway, leading to the prevention of tumor cell differentiation, reduced cell proliferation, and alleviated mouse intestinal inflammation. Here, IL17A is linked to neoplasm.